Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications quantitative benefit risk tradeoff preferences crohns disease treatment implications
… powerful tools for understanding the natural history and risk factors of a disease, for providing an opportunity to observe treatments … settings. In addition to providing the basis for multiple publications and presentations, these findings contribute …
… on the carer’s quality of life. Effective treatments can benefit caregivers as well as patients. However, inclusion of …
… New Real-World Evidence of Effective Treatment in Non-Small-Cell Lung Cancer with Capmatinib Share … 2023 Non-small cell lung cancer (NSCLC) is an aggressive disease, with poor prognosis and a high likelihood of brain … duration of response, time-to-treatment discontinuation, disease control rate, and progression-free survival in a …
… and Outcomes for Additional Screening for Ischemic Stroke Treatment OPPORTUNITY Our client wanted to understand if the … recombinant tissue plasminogen activator (IV tPA) treatment would be offset by improved clinical outcomes. …
… such as evidence regarding patient priorities and preferences, treatment burden, and burden of disease. Another important addition to the ICR for IPAY 2027 …
… and Strategy Team Offers: Extensive experience developing publications in pharmacoepidemiology, patient-centered … tactical plans efficiently and effectively. The Complete Publications Experience RTI-HS partners with you to develop … through increased knowledge and understanding. Our publications support spans the whole asset lifecycle and is …
Thirteenth Annual FDA Sentinel Initiative Public Workshop Share on: Monday, November 8, 2021, 10am - Tuesday, November 9, 2021, 2pm Workshop registration Image Bradley Layton, PhD , Senior Research Epidemiologist at RTI-HS, will be participating as a …
14th Annual Sentinel Initiative Public Workshop Share on: Tuesday, November 15 - Wednesday, November 16, 2022 Event webpage Bradley Layton, PhD, Director, Epidemiology at RTI Health Solutions is giving a presentation at the 14th Annual Sentinel …
… products targeted to Medicare-eligible populations Health benefit price benchmark (HBPB) ranges, using incremental cost … stakeholders: Consider potential differences in treatment efficacy in subgroups and identify key subgroups … (e.g., conduct surveys to obtain data on hours lost by the disease, health-related quality of life impact, burden of …
… View Now Generating and communicating evidence in COVID-19 treatment and vaccine development Although COVID-19-related … While companies race to be at the forefront of vaccine and treatment development, current strategies for evidence … have to be developed in the context of a rapidly evolving disease landscape. As we return to standard reimbursement …